Drugs for Plasmodium Vivax Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 53)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Piperaquine |
Approved, Experimental, Investigational |
Phase 4 |
|
4085-31-8 |
|
Synonyms:
1,3-Bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane
1,3-Bis(4-(7'-chloro-4'-quinoline)-1-piperazine)
1,3-Bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane
|
PIPERAQUINE
Piperaquinoline
|
|
2 |
|
Lumefantrine |
Approved |
Phase 4 |
|
82186-77-4 |
6437380 |
Synonyms:
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-a-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
(±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
Benflumetol
|
Benflumetol, (-)-isomer
Benflumetol, (+)-isomer
Benflumetol, (+-)-isomer
CPG-56695
DL-Benflumelol
GNF-PF-1971
LUMEFANTRINE
|
|
3 |
|
Tafenoquine |
Approved, Investigational |
Phase 4 |
|
106635-80-7 |
115358 |
Synonyms:
Krintafel
N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine
SB-252263AAB
Tafenoquine
|
Tafenoquine maleate
Tafenoquine succinate
WR 238605
WR-238605
|
|
4 |
|
Mefloquine |
Approved, Investigational |
Phase 4 |
|
53230-10-7 |
4046 |
Synonyms:
[(R*,S*)-2,8-BIS(TRIFLUOROMETHYL)QUINOLIN-4-YL]-(2-PIPERIDYL)METHANOL
a-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
GNF-PF-5544
GNF-Pf-5544|Lariam®|Ro-21-5998-001|WR-142490
Hoffmann la roche brand OF mefloquine hydrochloride
Hoffmann-la roche brand OF mefloquine hydrochloride
Lariam
MEFAQUIN
MEFLOQUIN
MEFLOQUINA
Mefloquine
|
MÉFLOQUINE
Mefloquine aziridine
Mefloquine HCL
Mefloquine hydrochloride
Mefloquinone
MEFLOQUINUM
Mephloquine
RO-215998
Roche brand OF mefloquine hydrochloride
WR-142490
Α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
|
|
5 |
|
Primaquine |
Approved |
Phase 4 |
|
90-34-6 |
4908 |
Synonyms:
6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline
8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline
8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline
Boucher and muir brand OF primaquine phosphate
Diphosphate, primaquine
Kanaprim
Neo-quipenyl
NSC-27296
Phosphate, primaquine
Primachin
Primachina
|
Primachinum
Primacin
Primaquin
Primaquina
PRIMAQUINE
Primaquine diphosphate
Primaquine phosphate
Primaquinum
SN-13272
WR-2975
|
|
6 |
|
Artesunate |
Approved, Investigational |
Phase 4 |
|
88495-63-0 |
6917864 5464098 |
Synonyms:
(3R,5AS,6R,8AS,9R,10S,12R,12AR)-DECAHYDRO-3,6,9-TRIMETHYL-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-OL HYDROGEN SUCCINATE
ARSUMAX
ARTESUNATE
Artesunato
Artesunatum
Artesunic acid
AS
Butanedioate, 1-[(3R,5as,6R,8as,9R,10S,12R,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-J]-1,2-benzodioxepin-10-yl] ester
Butanedioic acid, 1-[(3R,5as,6R,8as,9R,10S,12R,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-J]-1,2-benzodioxepin-10-yl] ester
Dihydroartemisinin, succinyl
|
Dihydroartemisinine 12 alpha succinate
Dihydroartemisinine-12-alpha-succinate
Dihydroqinghasu hemsuccinate
Dihydroqinghasu hemsuccinic acid
Malacef
Malartin
NSC-712571
Sodium artesunate
Succinyl dihydroartemisinin
|
|
7 |
|
Artemether |
Approved |
Phase 4 |
|
71963-77-4 |
68911 9796294 |
Synonyms:
(1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
alpha Artemether
alpha-Artemether
ARM566
Artemetero
ARTEMETHER
Artemether, (3R-(3alpha,5abeta,6alpha,8abeta,9alpha,10beta,12beta,12ar*))-isomer
Artemether, (3R-(3alpha,5abeta,6beta,8aalpha,9alpha,10beta,12beta,12ar*))-isomer
Artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12ar*))-isomer
ARTEMETHERI
Artemetherum
Artemisininelactol methyl ether
Artenam
b-Artemether
b-Dihydroartemisinin methyl ether
|
beta Arthemeter
beta-Artemether
beta-Arthemeter
beta-Dihydroartemisinin methyl ether
DIHYDROARTEMISININ IMPURITY G
Dihydroartemisinin methyl ether
DIHYDROQINGHAOSU METHYL ETHER
Methyl-dihydroartemisinine
NSC-665970
O Methyldihydroartemisinine
O-Methyldihydroartemisinine
SM 224
SM-224
Β-artemether
Β-dihydroartemisinin methyl ether
|
|
8 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
9 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
10 |
|
Artemether, Lumefantrine Drug Combination |
|
Phase 4 |
|
|
|
11 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
12 |
|
Anthelmintics |
|
Phase 4 |
|
|
|
13 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
14 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
15 |
|
Artemisinins |
|
Phase 4 |
|
|
|
16 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
17 |
|
Analgesics |
|
Phase 4 |
|
|
|
18 |
|
Artenimol |
Approved, Experimental, Investigational |
Phase 3 |
|
71939-50-9 |
540327 |
Synonyms:
3alpha-Hydroxydeoxydihydroartemisinin
8alpha-Hydroxydeoxyartemisinin
9alpha-Hydroxydeoxyartemisinin
ARTEMETHER RELATED COMPOUND A
ARTENIMOL
beta-Dihydroartemisinin
DIHYDROARTEMISININ
|
Dihydroartemisinine
Dihydroqinghaosu
Dihydroquinghaosu
Dihydroquinghaosu, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12alpha,12ar*))-isomer
Dihydroquinghaosu, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12alpha,12ar*))-isomer
GNF-PF-5634
|
|
19 |
|
Amodiaquine |
Approved, Investigational |
Phase 3 |
|
86-42-0 |
2165 |
Synonyms:
Amodiachin
Amodiaquin
Amodiaquina
Amodiaquine
Amodiaquine hydrochloride
Amodiaquine usp24
Amodiaquine, ring-closed
Amodiaquinum
Basoquin
CAM-AQ1
CAM-AQI
Camochin
|
Camoquin
Camoquin HCL
Camoquinal
Camoquine
Flavoquin
Flavoquine
GNF-PF-5648
Hydrochloride, amodiaquine
Miaquin
NSC-13453
Roussel brand OF amodiaquine hydrochloride
SJ000110703
|
|
20 |
|
Orange |
Approved |
Phase 3 |
|
|
|
21 |
|
Pyrimethamine |
Approved, Investigational, Vet_approved |
Phase 3 |
|
58-14-0, 19085-09-7 |
4993 |
Synonyms:
2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine
5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
Aventis brand OF pyrimethamine
CD
Chloridin
Chloridine
Chloridyn
Darachlor
Daraclor
Darapram
Daraprim
Daraprim®|GNF-Pf-5586|TCMDC-125860
Daraprime
Diaminopyritamin
Disulone
Erbaprelina
Ethylpyrimidine
Fansidar
Glaxo wellcome brand OF pyrimethamine
GlaxoSmithKline brand OF pyrimethamine
GNF-PF-5586
|
Khloridin
Malacid
MALACIDE
Malocid
Malocide
Maloprim
NSC-3061
Pirimecidan
Pirimetamin
Pirimetamina
Primethamine
Pyremethamine
Pyrimethamin
PYRIMETHAMINE
Pyriméthamine
Pyrimethamine Hcl
Pyrimethaminum
RP-4753
TCMDC-123831
TCMDC-125860
Tindurin
Tindurine
Tinduring
Wellcome brand OF pyrimethamine
WR-2978
|
|
22 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 3 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
23 |
|
Sulfadoxine |
Approved, Investigational |
Phase 3 |
|
2447-57-6 |
17134 |
Synonyms:
4-Sulfanilamido-5,6-dimethoxypyrimidine
4-Sulphanilamido-5,6-dimethoxypyrimidine
Fanasil
FANZIL
J21.373J
RO-44393
RO-4-4393
Roche brand OF sulfadoxine
Sulfadoxina
SULFADOXINE
Sulfadoxine roche brand
Sulfadoxinum
|
Sulformethoxine
Sulformetoxine
SULFORTHAMIDINE
Sulforthomidine
Sulphadoxina
Sulphadoxine
Sulphadoxinum
Sulphormethoxine
Sulphormetoxin
Sulphorthodimethoxine
Sulphorthomidine
WR-4073
|
|
24 |
|
Dapsone |
Approved, Investigational |
Phase 3 |
|
80-08-0 |
2955 |
Synonyms:
1,1'-Sulfonylbis(4-aminobenzene)
1,1'-Sulfonylbis[4-aminobenzene]
1,1'-Sulphonylbis(4-aminobenzene)
4-(4-Amino-benzenesulfonyl)-phenylamine
4-(4-Amino-benzenesulphonyl)-phenylamine
4-(4-Aminophenylsulfonyl)aniline
4-(4-Aminophenylsulfonyl)benzenamine
4-(4-Aminophenylsulphonyl)aniline
4-(4-Aminophenylsulphonyl)benzenamine
4,4' Diaminophenyl sulfone
4,4'-Dapsone
4,4'-Diaminodiphenyl sulfone
4,4'-Diaminodiphenyl sulphone
4,4'-Diaminodiphenylsulfone
4,4'-Diaminophenyl sulfone
4,4'-Sulfonylbisaniline
4,4'-Sulfonylbisbenzenamine
4,4'-Sulfonylbisbenzeneamine
4,4'-Sulfonyldianilin
4,4'-Sulfonyldianiline
4,4'-Sulphonylbisaniline
4,4'-Sulphonylbisbenzenamine
4-Aminophenyl sulfone
4-Aminophenyl sulphone
Acedapsone
Aczone
Araldite Ht
Avlosulfon
Avlosulfone
Avlosulphone
Bis(4-aminophenyl)sulfone
Bis(4-aminophenyl)sulphone
Bis(p-aminophenyl) sulfone
Bis(p-aminophenyl) sulphone
Croysulfone
Croysulphone
DADPS
Dapsoderm-X
Dapson
Dapsona
DAPSONE
Dapson-fatol
Dapsonum
DDS
Dds, Diaphenylsulfone
DDS, Pharmaceutical
Diaminodifenilsulfona
Diaminodiphenyl Sulfone
Diamino-diphenyl sulphone
Diaminodiphenylsulfone
|
Diaphenylsulfon
DIAPHENYLsulfone
Diaphenylsulphon
DIAPHENYLsulphone
Dimitone
Diphenasone
Diphone
Disulone
DSS
Dubronax
Dumitone
Eporal
Fatol brand OF dapsone
ICI
J04BA02
Metabolite C
Mex-america brand OF dapsone
N, N'-Diphenyl Sulfondiamide
Normet
Novophone
NSC-6091
NSC-6091D
Orsade brand OF dapsone
P, P'-Sulfonyldianiline
p,P'-diaminodiphenyl sulfone
p,P'-diaminodiphenyl sulphone
P,P-Diaminodiphenyl Sulphone
p,p-Sulfonylbisbenzamine
p,p-Sulfonylbisbenzenamine
p,p-Sulphonylbisbenzamine
p,p-Sulphonylbisbenzenamine
P,P-Sulphonyldianiline
p-Aminophenyl sulfone
p-Aminophenyl sulphone
Recolip
Sulfadione
Sulfanona-Mae
Sulfona
Sulfona-Mae
Sulfone Ucb
Sulfone, 4,4'-diaminophenyl
Sulfon-Mere
Sulfonyldianiline
Sulphadione
Sulphon-Mere
Sulphonyldianiline
Sumicure S
Tarimyl
Udolac
|
|
25 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
26 |
|
Chlorproguanil |
Investigational |
Phase 3 |
|
537-21-3 |
22323 9571037 |
Synonyms:
CHLORPROGUANIL
Chlorproguanilum
Clorproguanil
|
Lapudrine
mono-HCL OF Chlorproguanil
Unspecified HCL OF chlorproguanil
|
|
27 |
|
Pyronaridine |
Investigational |
Phase 3 |
|
74847-35-1 |
5485198 |
Synonyms:
2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine
4-((7-Chloro-2-methoxybenzo(b)(1,5)naphthyridin-10-yl)amino)-2,6-bis((pyrrolidin-1-yl)methyl)phenol
4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol
Benzonaphthyridine 7351
Malaridine
|
Phenol, 4-((7-chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)-, phosphate (1:4)
Pyronaridine
Pyronaridine phosphate salt
Pyronaridine tetraphosphate
|
|
28 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
29 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
30 |
|
Folate |
|
Phase 3 |
|
|
|
31 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
32 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
33 |
|
Fanasil, pyrimethamine drug combination |
|
Phase 3 |
|
|
|
34 |
|
Cobicistat |
Approved |
Phase 2 |
|
1004316-88-4 |
24950485 25151504 |
Synonyms:
1,3-THIAZOL-5-YLMETHYL [(2R,5R)-5-{[(2S)-2-({[(2-ISOPROPYL-1,3-THIAZOL-4-YL)METHYL](METHYL)CARBAMOYL}AMINO)-4-(MORPHOLIN-4-YL)BUTANOYL]AMINO}-1,6-DIPHENYLHEXAN-2-YL]CARBAMATE
COBICISTAT
GS 9350
|
GS-9350
N-[5-({hydroxy[(1,3-thiazol-5-yl)methoxy]methylidene}amino)-1,6-diphenylhexan-2-yl]-2-(N-methyl-N-{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}-(C-hydroxycarbonimidoyl)amino)-4-(morpholin-4-yl)butanimidate
TYBOST
|
|
35 |
|
Tinidazole |
Approved, Investigational |
Phase 2 |
|
19387-91-8 |
5479 |
Synonyms:
1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitroimidazole
Bioshik
CP-12574
Farmasierra brand OF tinidazole
Fasigin
Fasigyn
Fasigyne
Fasygin
Haisigyn
Pfizer brand OF tinidazole
Pierre fabre brand OF tinidazole
|
Simplotan
SYMPLOTAN
Teofarma brand OF tinidazole
Timidazole
Tindamax
Tinidazol
Tinidazole
Tinidazolum
Tricolam
TRIMONASE
|
|
36 |
|
Artefenomel |
Investigational |
Phase 2 |
|
1029939-86-3 |
24999143 |
Synonyms:
|
37 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
38 |
|
Vaccines |
|
Phase 2 |
|
|
|
39 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
40 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
41 |
|
Monatide (IMS 3015) |
|
Phase 2 |
|
|
|
42 |
|
Moxifloxacin |
Approved, Investigational |
Phase 1 |
|
186826-86-8, 354812-41-2, 151096-09-2 |
152946 |
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Actira
Avalox
Avelox
AVELOX I.V.
BAY 12-8039
|
Izilox
MOXIFLOXACIN
Moxifloxacin HCl
Moxifloxacin hydrochloride
Moxifloxacino
Octegra
Proflox
VIGAMOX
|
|
43 |
|
Sorbitol |
Approved, Investigational |
Phase 1 |
|
69-65-8, 50-70-4 |
453 6251 5780 |
Synonyms:
(-)-Sorbitol
(−)-SORBITOL
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
7B5697N
ALEXITOL SODIUM
ARIDOL KIT
Baxter brand OF sorbitol
Bronchitol
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-(-)-Sorbitol
D-(−)-SORBITOL
D-Glucitol
Diakarmon
Diosmol
D-Mannitol
D-Sorbit
D-SORBITOL
D-Sorbol
Dulcite
e 420
e 421
e420
e-420
e421
e-421
Esasorb
FEMA NO. 3029
Foodol D 70
FRAXININE
GLC-Ol
Glucarine
Glucitol
g-Ol
Hexahydroxyhexane
Hexanhexol
INS NO.421
INS-421
Invenex
ISOMALT IMPURITY, MANNITOL-
ISOMALT IMPURITY, SORBITOL-
Isotol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Manicol
MANITOL
Maniton S
Maniton-S
Manna sugar
Mannazucker
Mannidex
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
MANNITOLUM
|
Mannogem 2080
Marine crystal
Medefield brand OF sorbitol
Medevac
Multitol
Mushroom sugar
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb p 20/60
Neosorb p 60
Neosorb p 60W
Nivitin
NSC-25944
NSC-407017
Osmitrol
Osmofundin
Osmosal
Pfizer brand OF sorbitol
Resectisol
Resulax
SDM No. 35
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
SORBITOL
Sorbitol 3% in plastic container
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Tobrex
Trommsdorff brand OF sorbitol
Yal
|
|
44 |
|
Norgestimate, ethinyl estradiol drug combination |
|
Phase 1 |
|
|
|
45 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
46 |
|
Freund's Adjuvant |
|
Phase 1 |
|
|
|
47 |
|
diuretics |
|
Phase 1 |
|
|
|
48 |
|
Permethrin |
Approved, Investigational |
|
|
52645-53-1 |
40326 |
Synonyms:
(3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
(3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid
(3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
(m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate
3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane carboxylate, (3-phenoxyphenyl) methyl ester
3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl ester
3-Phenoxybenzyl-(+-)-cis,trans-2,2-dichlorovinyl-2,2-dimethyl-cyclopropylcarboxylic acid, ester
3-Phenoxybenzyl-cis,trans-(1Rs)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate
Ambush
cis Permethrin
cis-(1Rs)-Permethrin
cis-Permethrin
Cyclopropanecarboxylic acid, 3-(2,2-dichloroethenyl)-2,2-dimethyl-, (3-phenoxyphenyl)methyl ester
Elimite
LYCLEAR
LYTHRIN
Nittifor
NIX
NRDC 143
|
NRDC 147
NRDC143
NRDC-143
NRDC147
NRDC-147
PERMETHRIN
Permethrin, (1R-cis)-isomer
Permethrin, (1R-trans)-isomer
Permethrin, (1S-cis)-isomer
Permethrin, (1S-trans)-isomer
Permethrin, (cis-(+-))-isomer
Permethrin, (cis)-isomer
Permethrin, (trans-(+-))-isomer
Permethrin, (trans)-isomer
Permethrin, cis-(1Rs)-isomer
Permethrin, trans-(1Rs)-isomer
trans Permethrin
trans-(1Rs)-Permethrin
trans-Permethrin
|
|
49 |
|
Benzocaine |
Approved, Investigational |
|
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
50 |
|
Tannic acid |
Approved |
|
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
Interventional clinical trials:
(show top 50)
(show all 91)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand |
Unknown status |
NCT01662700 |
Phase 4 |
Artesunate;Chloroquine |
2 |
A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam |
Completed |
NCT01887821 |
Phase 4 |
Chloroquine;Dihydroartemisinin/Piperaquine |
3 |
Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area |
Completed |
NCT02118090 |
Phase 4 |
Chloroquine sulfate;DHA-PP |
4 |
Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial |
Completed |
NCT03916003 |
Phase 4 |
primaquine |
5 |
G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria |
Completed |
NCT02876549 |
Phase 4 |
Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly |
6 |
Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan |
Completed |
NCT01178021 |
Phase 4 |
Chloroquine;Chloroquine/Primaquine |
7 |
Short Course Radical Cure of P.Vivax in Nepal- a Randomized Controlled Trial |
Recruiting |
NCT04079621 |
Phase 4 |
primaquine |
8 |
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure |
Recruiting |
NCT04706130 |
Phase 4 |
Primaquine;Artesunate |
9 |
Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia |
Not yet recruiting |
NCT04704999 |
Phase 4 |
Tafenoquine;Chloroquine;Artemether 20 mg-Lumefantrine 120 mg |
10 |
A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil |
Terminated |
NCT01107145 |
Phase 4 |
Mefloquine- Artesunate;Artemether-Lumefantrine;Chloroquine |
11 |
Developing a Methodology to Assess 8-aminoquinoline Associated Haemolytic Risk in Females Heterozygous for G6PD in Endemic Populations |
Terminated |
NCT03337152 |
Phase 4 |
primaquine;chloroquine + primaquine |
12 |
Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine. |
Withdrawn |
NCT00290420 |
Phase 4 |
Chloroquine profilaxis |
13 |
Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia |
Unknown status |
NCT02348788 |
Phase 3 |
Artemether-lumefantrine + Primaquine;Chloroquine + Primaquine |
14 |
Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria |
Completed |
NCT02802501 |
Phase 3 |
Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment) |
15 |
Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan |
Completed |
NCT01625871 |
Phase 3 |
tablets artemether/lumefantrine |
16 |
Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup |
Completed |
NCT01288820 |
Phase 3 |
Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine |
17 |
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria |
Completed |
NCT02216123 |
Phase 3 |
Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo |
18 |
Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection |
Completed |
NCT02691910 |
Phase 2, Phase 3 |
Chloroquine;Primaquine |
19 |
A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria |
Completed |
NCT00440999 |
Phase 3 |
Pyronaridine artesunate;Chloroquine |
20 |
Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan |
Completed |
NCT00682578 |
Phase 3 |
Dihydroartemisinin + Piperaquine (Artekin);artesunate-sulphadoxin/pyrimethamine, chloroquine |
21 |
A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria. |
Completed |
NCT00158587 |
Phase 3 |
primaquine |
22 |
An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan |
Completed |
NCT00158561 |
Phase 3 |
sulfadoxine-pyrimethamine and chlorproguanil-dapsone |
23 |
Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan |
Completed |
NCT00158548 |
Phase 3 |
SP, chloroquine, amodiaquine, primaquine, artesunate |
24 |
Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax |
Completed |
NCT01640574 |
Phase 3 |
Dihydroartemisinin-Piperaquine;Chloroquine |
25 |
A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border |
Completed |
NCT01074905 |
Phase 3 |
Artesunate;Chloroquine;Chloroquine/Primaquine |
26 |
Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia |
Completed |
NCT01708876 |
Phase 3 |
Artesunate-mefloquine;Chloroquine;Primaquine |
27 |
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine - a Randomized Controlled Trial in P. Vivax Patients |
Recruiting |
NCT04411836 |
Phase 3 |
Tafenoquine;Primaquine |
28 |
An Open Label Randomized Comparative Study to Assess the Efficacy and Tolerability of Eurartesim® Versus Chloroquine and Nonrelapse Therapy With Primaquine for Uncomplicated Plasmodium Vivax Monoinfection Malaria |
Active, not recruiting |
NCT03208907 |
Phase 3 |
CQ coadministered with PQ;DHA-PQP coadministered with PQ;CQ and PQ starting on Day 42;DHA-PQP and PQ starting on Day 42 |
29 |
Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia |
Not yet recruiting |
NCT05232227 |
Phase 2, Phase 3 |
Primaquine double dose over 14 days;Primaquine single dose over 14 days |
30 |
A Phase III Randomised, Double-blind, Double-dummy, Comparative Study to Assess the Safety and Efficacy of Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children and Adult Patients in Korea With Acute P. Vivax Malaria |
Terminated |
NCT04368910 |
Phase 3 |
Pyronaridine - artesunate;Chloroquine |
31 |
A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period |
Completed |
NCT02123290 |
Phase 2 |
DSM265 400mg;DSM265 xmg;DSM265 ymg |
32 |
An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria |
Completed |
NCT02563496 |
Phase 2 |
Tafenoquine;Chloroquine |
33 |
A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK |
Completed |
NCT04009096 |
Phase 2 |
|
34 |
A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria. |
Completed |
NCT01376167 |
Phase 2 |
Chloroquine 600mg;Chloroquine 300mg;Tafenoquine 50mg;Tafenoquine 100mg;Tafenoquine 300mg;Tafenoquine 600mg;Primaquine 15mg;Chloroquine 600mg (Part 2 );Chloroquine 300mg (Part 2 );Tafenoquine 300mg (Part 2);Primaquine 15mg (Part2 ) |
35 |
Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults |
Completed |
NCT01157897 |
Phase 1, Phase 2 |
|
36 |
An Open Label Phase 2a Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of (+)-SJ000557733 (SJ733) With or Without Cobicistat in Adult Patients With Acute, Uncomplicated Malaria Over a 42 Day Period |
Completed |
NCT04709692 |
Phase 2 |
(+)-SJ000557733 (SJ733) |
37 |
Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax |
Completed |
NCT00811096 |
Phase 2 |
Tinidazole;chloroquine |
38 |
A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan. |
Completed |
NCT00486694 |
Phase 2 |
Sulfadoxine-pyrimethamine + artesunate;Chloroquine |
39 |
Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection |
Completed |
NCT01213966 |
Phase 2 |
OZ439 |
40 |
A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection |
Completed |
NCT01524341 |
Phase 2 |
KAE609 |
41 |
A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection |
Completed |
NCT01753323 |
Phase 2 |
KAF156 |
42 |
Phase IIB Study to Evaluate Primaquine Safety and Tolerability for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children < 15 Years-old (CHILDPRIM) |
Recruiting |
NCT05044637 |
Phase 2 |
Primaquine |
43 |
A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 in Healthy Adults Living in the UK |
Recruiting |
NCT04201431 |
Phase 1, Phase 2 |
|
44 |
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients |
Recruiting |
NCT03529396 |
Phase 2 |
Chloroquine;Primaquine |
45 |
A Phase II Clinical Study to Assess the Safety, Immunogenicity, and Efficacy of Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvRII/Matrix-M in Healthy Thai Adults Living in Thailand |
Not yet recruiting |
NCT05380388 |
Phase 2 |
|
46 |
Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers |
Not yet recruiting |
NCT04739917 |
Phase 2 |
|
47 |
Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria |
Terminated |
NCT02110784 |
Phase 2 |
Eurartesim tablets |
48 |
Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial |
Withdrawn |
NCT02696928 |
Phase 2 |
Artemeter-Lumefantrine and MB (combination therapy);Artemeter-Lumefantrine (combination therapy);Artemeter-Lumefantrine and Primaquine (combination therapy) |
49 |
Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria |
Completed |
NCT00295581 |
Phase 1 |
PpPfs25/ISA51 & ScPvs25/ISA51 |
50 |
Development of a Safe and Reproducible Human Sporozoite Challenge Model for Plasmodium Vivax in Healthy Adults in the United States |
Completed |
NCT00935623 |
Phase 1 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
halofantrine
Halofantrine hydrochloride
Mefloquine
|
Mefloquine Hydrochloride
Primaquine
Primaquine Phosphate
|
Cochrane evidence based reviews: malaria, vivax
|